G1 Therapeutics Inc Stock Ownership - Who owns G1 Therapeutics?

Insider buying vs selling

Have G1 Therapeutics Inc insiders been buying or selling?
Mark A. VellecaDirector2023-08-0857,286$0.39
Mark A. VellecaDirector2023-08-082,714$0.30
Mark A. VellecaDirector2023-08-082,714$2.02
Mark A. VellecaDirector2023-08-0857,286$2.00
John E. Jack Bailey Jr.President and CEO2023-07-052,719$2.45
Andrew PerryChief Commercial Officer2023-07-05355$2.45
Terry L. MurdockChief Operating Officer2023-07-051,361$2.45
Rajesh MalikChief Medical Officer2023-07-051,361$2.45
Jennifer K. MosesCFO2023-01-05729$5.41
James S. HansonGeneral Counsel2023-01-05729$5.41

1 of 2

GTHX insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when GTHX insiders and whales buy or sell their stock.

GTHX Shareholders

What type of owners hold G1 Therapeutics Inc stock?
Clay Thorp14.30%7,411,440$17.94MInsider
Ra Capital Management LP9.58%4,968,488$12.02MInsider
Fredric N. Eshelman7.12%3,689,151$8.93MInsider
Eshelman Ventures LLC6.63%3,439,151$8.32MInsider
Medimmune Ventures Inc5.69%2,950,630$7.14MInsider
Vanguard Group Inc3.76%1,950,068$4.72MInstitution
Blackrock Inc2.16%1,120,307$2.71MInstitution
Millennium Management LLC2.02%1,048,995$2.54MInstitution
Raymond James Associates1.79%925,776$2.24MInstitution
Jacobs Levy Equity Management Inc1.11%573,256$1.39MInstitution

1 of 3

GTHX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
GTHX21.11%46.30%Net Selling
THRX45.97%54.03%Net BuyingNet Buying
ABOS74.57%15.94%Net Buying
OMER42.89%6.17%Net BuyingNet Buying
KOD68.12%31.88%Net Selling

G1 Therapeutics Stock Ownership FAQ

Who owns G1 Therapeutics?

G1 Therapeutics (NASDAQ: GTHX) is owned by 21.11% institutional shareholders, 46.30% G1 Therapeutics insiders, and 32.59% retail investors. Clay Thorp is the largest individual G1 Therapeutics shareholder, owning 7.41M shares representing 14.30% of the company. Clay Thorp's G1 Therapeutics shares are currently valued at $23.57M.

If you're new to stock investing, here's how to buy G1 Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.